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Abstract
Allergen-specific immunotherapy (AIT) is the only allergy 
treatment that confers long-term symptom amelioration for 
patients suffering from allergy. The most frequently used al-
lergen application route is subcutaneous injection (SCIT), 
commonly taken as the gold standard, followed by sublin-
gual (SLIT) or oral (OIT) application of allergen preparations. 
This is an up-to-date review of the clinical evidence for a 
novel route of allergen application, i.e., directly into lymph 
nodes – intralymphatic immunotherapy (ILIT). The major ad-
vantages of ILIT over the current AIT approaches are its short 
duration and the low allergen doses administered. The 
whole treatment consists of merely 3 ultrasound-guided in-
jections into inguinal lymph nodes 1 month apart. While the 
number of patients included in randomised controlled trials 
is still limited, the clinical results for ILIT are encouraging, but 
more clinical trials are needed, as well as more preclinical 
work for optimising formulations. © 2018 S. Karger AG, Basel
Edited by: H.-U. Simon, Bern.
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ILIT Updated
Introduction
Allergen-specific immunotherapy (AIT) is the only al-
lergy treatment that confers long-term symptom amelio-
ration. AIT administers gradually increasing allergen 
doses to the allergic individual, thereby altering the im-
mune response to the allergen. The most frequently used 
allergen application route is subcutaneous injection, 
commonly taken as the gold standard, followed by sub-
lingual or oral application. Epicutaneous and intralym-
phatic (ILIT) routes of application are currently in clini-
cal development. Also, intradermal [1] and local nasal [2] 
routes have been explored. AIT has recently been re-
viewed [3, 4].
The effectiveness and the efficacy of the diverse ap-
proaches in AIT depend largely on the composition and 
formulation of the applied allergen, recently reviewed by 
Akdis and Akdis [5], as well as on adjuvants, recently re-
viewed by Chesné et al. [6]. An all-encompassing review 
was scheduled for 2016 by the European Academy of Al-
lergy and Clinical Immunology (EAACI) [7].
A PubMed search for controlled clinical trials in early 
2016 yielded more than 120 publications on subcutane-
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Fig. 1. a Sonographic view of a needle po-
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matic view of the injection protocol for 
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ous immunotherapy (SCIT), over 300 on sublingual im-
munotherapy (SLIT) and oral immunotherapy (OIT), 17 
on local nasal immunotherapy, 5 on epicutaneous immu-
notherapy (EPIT), 4 on intralymphatic immunotherapy 
(ILIT), and 1 on intradermal immunotherapy (with pep-
tides for Treg induction). With the exception of SLIT, 
most clinical trials were conducted with relatively small 
numbers of patients, and with a diversity of allergens, ad-
juvants, and formulations. 
The scarcity of investigations into novel routes may at 
least in part be due to new regulations which currently 
force the industry to officially register their therapeutic 
allergen extracts. Thus, the industry is currently focussed 
on efficacy trial programs to keep existing products on 
the market. Another reason for the lack of commercial 
interest may be that the newer methods such as ILIT tend 
to use much less allergen. On the other hand, a recent ma-
jor production bottleneck of one major supplier of im-
munotherapeutic vaccines has compromised treatment 
cycles of SCIT in Europe [8], highlighting an advantage 
of immunotherapy methods with fewer and lower-dose 
vaccine applications that may be less affected by a com-
promised supply chain.
ILIT is one such application route requiring merely 3 
ultrasound-guided injections of low allergen doses into 
inguinal lymph nodes with a 1-month time interval 
(Fig. 1). The entire treatment is therefore finished after 2 
months. In comparison, SCIT with common marketed 
allergen extracts requires up to 70 injections and visits to 
a medical practice over a time period of up to 5 years, 
something that only 5% of eligible patients judge worth 
the inconvenience [9]. ILIT poses a viable alternative to 
overcome the most urgent problem with long-term SCIT 
and SLIT management, oftentimes overlooked by the 
medical community, i.e., non-adherence to treatment 
[10]. ILIT considerably reduces the resource overhead for 
the patient, the physician, and the reimbursing party. Fi-
nally, the relatively short treatment interval avoids using 
multiple batches of vaccine or treatment interruptions 
due to supply chain bottlenecks. If a single batch of vac-
cine is not in stock for a whole treatment cycle, the im-
munotherapy will not be started until supply is resumed, 
thus avoiding interruptions, premature terminations, or 
adverse reactions due to change of batches during the 
course of AIT that might lead to an unsatisfactory out-
come.
ILIT Clinical Trials
In Table 1 we present all clinical trials (n = 8) published 
to date on intralymphatic allergen immunotherapy, in-
cluding 175 patients receiving intralymphatic injections 
of verum and 83 and 54 receiving placebo or SCIT, re-
spectively. In 2015, Senti et al. [11] reviewed the accumu-
lated experience in ILIT up to 2014. They reviewed all 4 
clinical trials on ILIT in humans published until mid-
2014 [12–15]. Their conclusion from the 4 trials was that 
they indicate ILIT against grass pollen and bee venom to 
not only be safe and efficient, but also associated with a 
lower risk of systemic adverse effects (e.g., anaphylaxis 
and lethal consequences). With only 3 injections in 3 
months, symptom relief was documented as comparable 
with standard SCIT requiring up to 100 injections over 
3–5 years. The immunological data of one of these trials, 
in which the major cat dander allergen was fused with a 
molecular antigen transportation system (MAT-Fel d 1), 
has meanwhile been worked up in detail by Zaleska et al. 
[16]. 
In 2016, Hylander et al. [9] reported a double-blinded 
placebo-controlled clinical trial in 36 patients with birch- 
or grass pollen-induced rhinoconjunctivitis and conclud-
ed that ILIT is an effective and safe therapy for this condi-
tion, resulting in a marked reduction of seasonal allergic 
symptoms. In the same year Patterson et al. [17] pub-
lished a randomised, double-blind, placebo-controlled, 
parallel group pilot study in 15 adolescents in the USA 
with bothersome nasal, ocular, and/or respiratory symp-
toms correlating with the timing of the grass pollen sea-
son and evidence of grass pollen sensitisation. They con-
cluded ILIT to be efficacious and safe, and recorded no-
tably low adverse reactions.
All ILIT trials so far have noted a clinical improvement 
except for the one reported by Witten et al. [15] that 
showed immunological changes but no clinical improve-
ment. If anything, symptoms tended to worsen. In con-
trast to all other successful trials, the interval between in-
jections in that trial by Witten et al. [15] was shorter than 
in other trials, i.e., 2 instead of 4 weeks. This may explain 
the missing clinical effect as time intervals shorter than 2 
weeks are known to compromise memory B cell forma-
tion and affinity maturation [18, 19]. It is well known in 
vaccine immunology that both these processes require 
periods where antigen levels are low, so that there is com-
petition for the antigen in germinal centres that can pos-
itively select high-affinity B cells [18].
An open label pilot study with 7 patients with grass 
pollen-related seasonal rhinoconjunctivitis showed an 
induction of allergen-specific plasmablasts expressing 
other isotypes than IgE and a trend towards improve-
ment of symptoms, medication score, and rhinocon-
junctivitis-related quality of life during one pollen season 
Senti et al.Int Arch Allergy Immunol4
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[20]. Another open label pilot study with 11 patients suf-
fering from rhinoconjunctivitis caused by house dust 
mite, cat or dog allergens, or a combination thereof, in-
dicated a risk of systemic adverse effects after ILIT but 
also found that ILIT can rapidly improve allergic rhinitis 
symptoms and reduce the frequency of prescription of 
rescue medication, and that the effect lasted for 1 year 
[21]. 
The only long-term study published to date [14] 
showed a sustained clinical benefit (up to 3 years) in terms 
of symptom reduction, comparable to SCIT. One trial 
with 60 patients randomised 1: 1 to receive combined in-
jections of birch and grass pollen allergen or placebo 
found the treatment to be safe and effective [22]. The sum 
of nasal symptoms was reduced by 25% at follow-up after 
6–9 months in the verum group, whereas no reduction 
was observed in the placebo group. The authors also 
found as a first-time discovery mirrored in the blood an 
increased proportion of effector memory T cells in lymph 
node-derived cells.
Endpoints
Clinical trials in AIT have subjective patient-related 
outcomes and objective read-outs. A recent EAACI po-
sition paper concluded that the most recommended 
subjective scoring is the combined symptom-medica-
tion score [23]. Quality of life, challenge testing, and im-
munological outcomes can be used as secondary efficacy 
parameters. As listed in Table 1, all ILIT clinical trials 
have used subjective symptoms recorded by patients as 
an endpoint. One trial used a combined score of symp-
toms and rescue medication as an endpoint. Various 
scores or visual analogue scales were used to quantify the 
symptoms in other studies. Use of rescue medication 
was an endpoint in 3 trials. Two trials used a rhinocon-
junctivitis quality of life questionnaire, the original 
“RQLQ” [24] and the validated “mini-RQLQ” [25], re-
spectively. Further endpoints were: (i) nasal symptoms 
after a nasal provocation test in 3 trials, (ii) immuno-
logical parameters (circulating IgE and/or IgG4 levels, 
and T cell analyses) in 3 trials, (iii) skin-prick test in 3 
trials, and (iv) nasal lavage fluid parameters in 1 trial. All 
trials also recorded adverse events according to regula-
tions and local reactions at the injection site as safety 
endpoints.
There is no consistency in the choice of endpoints ex-
cept subjective symptom scores. For the assessment of 
symptoms, a diversity of non-standard and non-validated 
scoring methods were used, except for 3 trials using 
RQLQ.
Allergen Extracts Used
Table 1 shows that in 5 ILIT clinical trials with patients 
suffering from seasonal grass and/or birch allergic rhini-
tis or rhino-conjunctivitis (ARC), commercially available 
grass pollen extract was injected, and in 2 of these trials 
commercially available birch pollen extract was used in 
the ARC patients with birch allergy. One trial used a re-
combinant MAT-Fel d 1 vaccine produced in a GMP fa-
cility in patients suffering from cat dander ARC [13]. All 
but one [21] of the ILIT clinical trials used aluminium 
hydroxide-adsorbed antigen as vaccines. None of the 
ILIT trials used any additional adjuvant.
The first ILIT open-label clinical trial [14] was re-ana-
lysed for methodological effects in measuring and analys-
ing the efficacy of immunotherapies of grass pollen al-
lergy [26]. The conclusions included a need for method-
ological recommendations, as the choice of analytical 
methods affects the outcome.
One pilot study [21] also used combinations of aller-
gen extracts according to the hypersensitivity pattern of 
the patient. One trial used a combined injection of birch 
and grass pollen allergen [22].
Immunology of ILIT
More than 20 years ago, Kündig et al. [27] proposed a 
simple geographical model of immunogenicity, i.e., that 
antigens in the periphery are largely ignored, whereas an-
tigens which reach a lymph node, either by being drained 
there or by being transported there by dendritic cells, are 
strongly immunogenic. One important reason for the 
fact that a lymph node is such an immunogenic environ-
ment is the high probability for an antigen to meet a spe-
cific T or B cell, which is orders of magnitude higher than 
with peripherally administered antigens, because of the 
enormous density of T and B cells. ILIT has proved to 
enhance the immune response when using various types 
of vaccines, i.e., proteins, peptides, mRNA, naked DNA, 
bacteria, immunostimulatory complexes (ISCOMS), vi-
rus-like particles, and dendritic cells. Also, ILIT has been 
successfully performed in various animal species, such as 
mice, rats, dogs, horses, ponies, cows, and monkeys, as 
reviewed previously [28]. When analysing human sera 
after ILIT with MAT-Fel d 1, Freiberger et al. [29] re-
cently found that the predominant immunoglobulin 
subclass was IgG4, whereas only marginal levels of IgG1, 
IgG2, and IgG3 were induced. We previously showed 
that this predominant IgG4 induction correlated with 
the allergen-specific IL-10-producing T cell response 
[13]. Further analyses confirmed that early allergen-spe-
cific T cell activation by ILIT was followed by T cell un-
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responsiveness to allergen, characterised by increased 
allergen-specific IL-10-producing Treg cells expressing 
FOXP3 [16].
ILIT and Unmet Needs
Only a few trials reported systemic adverse reactions 
after intralymphatic administration of antigen. As the 
needle penetrates all skin layers before reaching the lymph 
node it is possible that antigen solution leaks from the 
needle tip into those layers or even into inadvertently 
penetrated vessels. The ultrasound-guided targeting of 
the lymph node may not be precise enough in every case 
to exclude the possibility of inadvertently injecting anti-
gen into surrounding subcutaneous tissue. Both situa-
tions should only rarely occur in the hands of adequately 
trained personnel. The requirement of ultrasound equip-
ment may be considered a drawback of this therapeutic 
approach, and the inguinal site of injection may not be 
appealing to some patients.
Despite the predominantly favourable reports of clini-
cal trials with ILIT and the observed immunologic chang-
es that together can be taken as proof of concept, there is 
as yet not enough convincing evidence for a routine use of 
ILIT in treating allergic conditions, nor is there any autho-
rised product for ILIT commercially available in any coun-
try. The most pressing unmet need is not only for higher 
numbers of patients/controls and more multicentric pro-
spective randomised controlled double-blinded clinical 
trials, but also for the use of more diverse allergens. While 
grass or birch pollen and cat dander allergies are among the 
most frequent allergies that are not easily avoidable, world-
wide the most important allergen is house dust mite. There 
are many more seasonal and perennial allergic conditions 
waiting for shortened AIT regimes. Also, a shorter and ef-
fective immunotherapy for insect venom hypersensitivity 
would be most welcome for affected patients, as the fre-
quency of adverse events with the rush-build-up schedule 
of venom immunotherapy is still considerable. More bench 
work followed by clinical testing is also needed for optimis-
ing the vaccines. The vaccines tested so far were all ad-
sorbed to aluminium hydroxide with no other and more 
potent biological response modifiers added. There is a 
good deal of know-how in the field of immunisation that 
could be applied to ILIT. Another major unmet need that 
is not specific to ILIT or AIT in general is the harmonisa-
tion of inclusion/exclusion criteria, endpoints, and detec-
tion/monitoring methods in allergy trials. Whereas there 
is a consensus in choosing subjective symptoms as a major 
endpoint, there are no common procedures in quantifying 
or assessing symptoms, or for including the effect of med-
ication usage on symptom scores. The same is true for 
many “objective” endpoints, where there is a diversity in 
analytical methods, validated or not, with untrusted refer-
ence ranges. All this hampers the statistical power of any 
single trial and robustness of meta analyses. Table 2 lists 
common items that need to be agreed on in order to max-
imise the scientific and clinical gain of knowledge with the 
limited financial resources available for clinical trials and 
basic research. Previously published guidelines recom-
mending how to standardise AIT trials [30] and AIT trial 
outcomes [23] could be tailored to the specific needs of 
ILIT trials. ILIT continues to be underexplored in paediat-
Table 2. Open questions or missing consensus, common to ILIT 
and other AIT
Questions/problems
Patient eligibility
Mono-allergic
Poly-allergic
Minimal age
Comorbidities
Administration schedule
Number of injections
Interval
Pre-/co-/post-seasonal
Dosage
Amount
Volume
Concentration
Constant
Escalating
Standardisation
Biological
Immunological
Reference
Vaccine
Choice
Production
Mix
Adjuvants
Choice
Dose/concentration
Outcome measuring
Symptoms/quality of life
Functional tests
Laboratory parameters
Study design
Mono-/multicentric
Open label/blinded
Prospective/retrospective
Registry
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ric patients and further investigation in this population is 
mandatory to establish adequate clinical guidelines of its 
indications and outcomes. It may be worth mentioning 
that ILIT has recently been successfully tested for the treat-
ment of canine atopic dermatitis [31].
Conclusion
With the 6 clinical trials reported so far with: (i) a total 
of 134 patients receiving intralymphatic injections of verum 
and 53 and 54 receiving placebo or SCIT, respectively, (ii) 
inconsistent endpoints with non-uniform methods of as-
sessing endpoints, (iii) often small difference (delta), and 
(iv) inconsistent and mainly short follow-ups, the overall 
statistical power is obviously moderate. Nonetheless, all but 
1 study reported desirable measurable effects compared to 
controls (placebo in 5, SCIT in 1 trial). This effect of the in-
tervention observed across the studies and consistently 
pointing in the same direction is likely to support the find-
ings of Atkins et al. [32]. Only 1 study reported an effect on 
immunological parameters, but no symptomatic improve-
ment compared to placebo [15]. It is worth noting that the 
only long-term study published to date [14] showed sus-
tained symptom reduction for up to 3 years, representing a 
clinical benefit comparable to SCIT. Although this evidence 
needs to be confirmed by further studies, this may suggest 
that a persistent effect may be obtained by a short course of 
ILIT. While it is still too early to recommend ILIT for clin-
ical use, proof of principle is established. Unanimously, the 
trials found ILIT to be safe. With only 3 injections with 
1-month time intervals, and therefore a treatment duration 
of merely 2 months, the inconvenience for the patient and 
the overhead for the clinical practice is considerably lower 
than with up to 70 practice visits for injections over up to 5 
years for the gold standard SCIT, thus enhancing treatment 
adherence. The health economic impact [33, 34] of ILIT 
may be substantial due to reduced consumption of resourc-
es during treatment, but also, when successful, due to re-
duced use of rescue medication for symptomatic treatment 
and fewer sick leaves.
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